Sikora Aleksandra, Sullivan Kevin M, Dineen Sean, Raoof Mustafa, Karolak Aleksandra
Department of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
Mol Ther Oncol. 2024 Jan 29;32(1):200767. doi: 10.1016/j.omton.2024.200767. eCollection 2024 Mar 21.
Peritoneal metastases from gastrointestinal malignancies present difficult management decisions, with options consisting primarily of systemic chemotherapy or major surgery with or without hyperthermic intraperitoneal chemotherapy. Current research is investigating expanding therapeutic modalities, and the aim of this review is to provide an overview of the existing and emerging therapies for the peritoneal metastases from gastrointestinal cancers, primarily through the recent literature (2015 and newer). These include the current data with systemic therapy and cytoreduction with hyperthermic intraperitoneal or pressurized intraperitoneal aerosol chemotherapy, as well as novel promising modalities under investigation, including dominating oncolytic viral therapy and adoptive cellular, biologic, and bacteria therapy, or nanotechnology. The novel diverse strategies, although preliminary and preclinical in murine models, individually and collectively contribute to the treatment of peritoneal metastases, offering hope for improved outcomes and quality of life. We foresee that these evolving treatment approaches will facilitate the transfer of knowledge and data among studies and advance discovery of new drugs and optimized treatments for patients with peritoneal metastases.
胃肠道恶性肿瘤的腹膜转移带来了艰难的治疗决策，主要治疗选择包括全身化疗或进行或不进行腹腔内热化疗的大型手术。目前的研究正在探索更多的治疗方式，本综述的目的是主要通过近期文献（2015年及之后）概述胃肠道癌症腹膜转移的现有和新兴治疗方法。这些方法包括全身治疗和腹腔内热化疗或腹腔内加压气溶胶化疗减瘤的当前数据，以及正在研究的有前景的新方法，包括主要的溶瘤病毒疗法、过继性细胞、生物和细菌疗法或纳米技术。这些新颖多样的策略虽然在小鼠模型中尚处于初步和临床前阶段，但单独或共同地都有助于腹膜转移的治疗，为改善治疗结果和生活质量带来了希望。我们预计，这些不断发展的治疗方法将促进研究之间的知识和数据交流，并推动针对腹膜转移患者的新药发现和优化治疗。
